Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases.
Paul MartinJames DingKate DuffusVasanthi Priyadarshini GaddiAmanda McGovernHelen Ray-JonesAnnie YarwoodJane WorthingtonAnne BartonGisela OrozcoPublished in: Annals of the rheumatic diseases (2019)
Capture Hi-C has the potential to identify therapies which could be repositioned to treat rheumatic diseases. This was particularly successful for rheumatoid arthritis, where six effective, biologic treatments were identified. This approach may therefore yield new ways to treat patients, enhancing their quality of life and reducing the economic impact on healthcare providers. As additional cell types and other epigenomic data sets are generated, this prospect will improve further.
Keyphrases
- rheumatoid arthritis
- healthcare
- genome wide
- end stage renal disease
- single cell
- ejection fraction
- chronic kidney disease
- newly diagnosed
- dna damage
- peritoneal dialysis
- dna methylation
- cell therapy
- transcription factor
- disease activity
- patient reported outcomes
- copy number
- electronic health record
- big data
- emergency department
- mesenchymal stem cells
- risk assessment
- current status
- social media
- systemic lupus erythematosus
- artificial intelligence
- data analysis
- systemic sclerosis